CSPC Pharmaceutical (HKG:1093) granted an exclusive license to Cipla USA to sell its irinotecan liposome injection in the US, according to a Thursday filing with the Hong Kong bourse.
The injection is indicated for the treatment of multiple solid tumors such as metastatic pancreatic cancer, colorectal cancer, lung cancer, and cervical cancer, the filing said.
Under the agreement, CSPC Pharma will get an upfront payment of $15 million and may be eligible to obtain up to $25 million in potential first commercial sale and regulatory milestone payments.
CSPC could also receive up to $1.03 billion in additional commercial sales milestone payments, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.